Small-Molecule Antiviral β-d-N(4)-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance

Coronaviruses (CoVs) have emerged from animal reservoirs to cause severe and lethal disease in humans, but there are currently no FDA-approved antivirals to treat the infections. One class of antiviral compounds, nucleoside analogues, mimics naturally occurring nucleosides to inhibit viral replicati...

Descripción completa

Detalles Bibliográficos
Autores principales: Agostini, Maria L., Pruijssers, Andrea J., Chappell, James D., Gribble, Jennifer, Lu, Xiaotao, Andres, Erica L., Bluemling, Gregory R., Lockwood, Mark A., Sheahan, Timothy P., Sims, Amy C., Natchus, Michael G., Saindane, Manohar, Kolykhalov, Alexander A., Painter, George R., Baric, Ralph S., Denison, Mark R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2019
Materias:
Vaccines and Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6880162/
https://www.ncbi.nlm.nih.gov/pubmed/31578288
http://dx.doi.org/10.1128/JVI.01348-19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6880162/
https://www.ncbi.nlm.nih.gov/pubmed/31578288
http://dx.doi.org/10.1128/JVI.01348-19

Ejemplares similares